Harish Chowdary Gorrepati/LinkedIn
Sep 1, 2026, 15:09
Harish Chowdary Gorrepati: The HALT Paradox After TAV
Harish Chowdary Gorrepati, Interventional Cardiologist at Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati, Fellow at Heart Center UMC, shared a post on LinkedIn:
“NOTION-4 Trial | TAVR and Antithrombotic Therapy.
Short-term DOAC after TAVR significantly reduced HALT at 3 months (31.8 percent – 12.1 percent), but this benefit was not sustained at 12 months (32.2 percent versus 28.3 percent; P=0.54).
Importantly, bleeding/clinical events were numerically higher with the DOAC strategy.
Key message: Reducing leaflet thrombosis on CT does not necessarily translate into better clinical outcomes.
SAPT remains the preferred strategy for patients without another indication for oral anticoagulation.”
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 14:53Josef Kroupa: Landmark PRAGUE-26 Trial Advances Interventional PE Treatment
-
Sep 1, 2026, 14:34Marcin Kurzyna: New NEJM Trial Evaluates Catheter-Directed Thrombolysis in PE
-
Sep 1, 2026, 14:18Rafael Gomes: CoCAP Study Challenges Prolonged DAPT After CABG
-
Sep 1, 2026, 09:16Nicolas Gendron: Real-World Data on Danaparoid in Patients with Suspected HIT
-
Sep 1, 2026, 08:24Cristina Chang: The Importance of The New ET Treatments
-
Sep 1, 2026, 07:22Abdul Mannan: ASH 2026 Guidelines – New Treatment Approach for Adult ITP
-
Sep 1, 2026, 07:20Alejandro González Veliz: Silent Atherosclerosis Starts Earlier Than We Think
-
Sep 1, 2026, 07:18Alan Nurden: A New Mechanism Behind Immune Thrombocytopenia
-
Sep 1, 2026, 07:18Susan Shea: New NHLBI Fellowship Supports Thrombinflammation Research